Dear E-druggers,
It is not my intention to participate in the patent rights debate as I think
the issue has been well covered by Carolyn and Joel. What I would like to
add, though concerning ciprofloxacin, is that I am concerned that a too
cheap source might cause a worrisome overuse. The fluoroquinolones are
useful antibiotics, but has a troublesome side effect in children on the
ligaments and use in children is not recommended in many countries. Of more
concern, however, is the rapid increase in resistance. The last study to
point to this problem was published in Lancet 18 january. A Danish study
found that quinolone excretion into the sweat caused rapid development of
multiresistant S. epidermidis. That mechanisms of quinolone resistance in
staphylococci are still unknown, does not sound reassuring either.
I hope at least E-druggers are using quinolones wisely!
Regards
Ms Kirsten Myhr, MScPharm, MPH
Bygdoy Alle 58B
0265 Oslo
Norway
Tel: +47 22 56 05 85 (h)
Fax: +47 22 24 90 17 (w) Tel: +47 22 24 90 39 (w)
E-mail: myhr@online.no
or (w): kirsten.myhr@helsetilsynet.dep.telemax.no
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.